Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
97 hedge funds and large institutions have $126M invested in Y-mAbs Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 36 reducing their positions, and 19 closing their positions.
7,450% more call options, than puts
Call options by funds: $151K | Put options by funds: $2K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $128M → $126M (-$1.76M)
2.1% less ownership
Funds ownership: 63.7% → 61.61% (-2.1%)
5% less funds holding
Funds holding: 102 → 97 (-5)
22% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 36
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.58M |
| 2 |
ACA
Acorn Capital Advisors
New York
|
+$825K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$744K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$693K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$618K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
-$1.96M |
| 2 |
Millennium Management
New York
|
-$1.47M |
| 3 |
Morgan Stanley
New York
|
-$933K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$904K |
| 5 |
BlackRock
New York
|
-$692K |
YMAB Hedge Fund Activity: Q2 2025 in Review
97 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2025, worth a combined $126M — down 1.4% from $128M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of YMAB and 14 opened new positions — a net loss of 5 holders — while 36 trimmed existing stakes and 28 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $1.58M. The largest seller was Pictet Asset Management, exiting entirely with an estimated $1.96M sold.
- 97 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2025, down from 102 in Q1 2025.
- Funds reported $126M of Y-mAbs Therapeutics stock for Q2 2025, down 1.4% quarter-over-quarter.
- 14 funds opened new Y-mAbs Therapeutics positions in Q2 2025 and 19 closed out, a net change of -5 holders.
- The largest Y-mAbs Therapeutics buyer in Q2 2025 was Nantahala Capital Management, an estimated $1.58M added.
- The largest Y-mAbs Therapeutics seller in Q2 2025 was Pictet Asset Management, an estimated $1.96M sold.
Based on aggregated 13F filings for Q2 2025.